CO4480020A1 - PHARMACEUTICAL FORMULATIONS - Google Patents

PHARMACEUTICAL FORMULATIONS

Info

Publication number
CO4480020A1
CO4480020A1 CO96061449A CO96061449A CO4480020A1 CO 4480020 A1 CO4480020 A1 CO 4480020A1 CO 96061449 A CO96061449 A CO 96061449A CO 96061449 A CO96061449 A CO 96061449A CO 4480020 A1 CO4480020 A1 CO 4480020A1
Authority
CO
Colombia
Prior art keywords
formulation according
active drug
molecular weight
aqueous media
active
Prior art date
Application number
CO96061449A
Other languages
Spanish (es)
Inventor
Ross James Macrae
Janet Sarah Smith
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of CO4480020A1 publication Critical patent/CO4480020A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. UNA FORMULACION FARMACEUTICA DE LIBERACION CONTROLADA PARA LA ADMINISTRACION ORAL, COMPUESTA ESENCIALMENTE POR: UN FARMACO ACTIVO; POLI(OXIDO DE ETILENO) DE BAJO PESO MOLECULAR; HIDROXIPROPIL- METIL CELULOSA; EXCIPIENTES DE COMPRIMIDOS; Y OPCIONALMENTE UNO O MAS POLIMEROS ENTERICOS. 2. UNA FORMULACION SEGUN LA REIVINDICACION 1, EN LA QUE EL FARMACO ACTIVO ES DEBILMENTE BASICO. 3. UNA FORMULACION SEGUN LA REIVINDICACION 1 O LA REIVINDICACION 2, EN LA QUE EL FARMACO ACTIVO ES DOXAZOSINA, O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES. 4. UNA FORMULACION SEGUN LA REIVINDICACION 1, EN LA QUE EL FARMACO ACTIVO TIENE UNA ALTA SOLUBILI- DAD EN MEDIOS ACUOSOS. 5. UNA FORMULACION SEGUN LA REIVINDICACION 1, EN LA QUE EL FARMACO ACTIVO TIENE UNA BAJA SOLUBILI- DAD EN MEDIOS ACUOSOS. 6. UNA FORMULACION SEGUN UNA CUALQUIERA DE LAS REIVINDICACIONES ANTERIORES, EN LA QUE LA HIDROXI- PROPILMETIL CELULOSA TIENE UN PESO MOLECULAR MEDIO NUMERICO EN EL INTERVALO DE 80.000 A 250.000.1. A PHARMACEUTICAL FORMULATION OF CONTROLLED RELEASE FOR THE ORAL ADMINISTRATION, COMPOSED ESSENTIALLY BY: AN ACTIVE PHARMACY; LOW MOLECULAR WEIGHT POLY (ETHYLENE OXIDE); HYDROXIPROPIL-METHYL CELLULOSE; EXCIPIENTS OF TABLETS; AND OPTIONALLY ONE OR MORE ENTERIC POLYMERS. 2. A FORMULATION ACCORDING TO CLAIM 1, IN WHICH THE ACTIVE DRUG IS WEAKLY BASIC. 3. A FORMULATION ACCORDING TO CLAIM 1 OR CLAIM 2, IN WHICH THE ACTIVE DRUG IS DOXAZOSINE, OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS. 4. A FORMULATION ACCORDING TO CLAIM 1, IN WHICH THE ACTIVE DRUG HAS A HIGH SOLUBILITY IN AQUEOUS MEDIA. 5. A FORMULATION ACCORDING TO CLAIM 1, IN WHICH THE ACTIVE DRUG HAS A LOW SOLUBILITY IN AQUEOUS MEDIA. 6. A FORMULATION ACCORDING TO ANY OF THE PREVIOUS CLAIMS, IN WHICH THE HYDROXY-PROPYLMETHYL CELLULOSE HAS A NUMERICAL AVERAGE MOLECULAR WEIGHT IN THE INTERVAL OF 80,000 TO 250,000.

CO96061449A 1995-11-21 1996-11-21 PHARMACEUTICAL FORMULATIONS CO4480020A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9523752.5A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CO4480020A1 true CO4480020A1 (en) 1997-07-09

Family

ID=10784188

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96061449A CO4480020A1 (en) 1995-11-21 1996-11-21 PHARMACEUTICAL FORMULATIONS

Country Status (29)

Country Link
EP (1) EP0862437A1 (en)
JP (1) JPH10513481A (en)
KR (1) KR19990071505A (en)
CN (1) CN1215993A (en)
AP (1) AP718A (en)
AR (1) AR004335A1 (en)
AU (1) AU709560B2 (en)
BG (1) BG102438A (en)
BR (1) BR9611626A (en)
CA (1) CA2232715A1 (en)
CO (1) CO4480020A1 (en)
CZ (1) CZ155498A3 (en)
GB (1) GB9523752D0 (en)
HR (1) HRP960554A2 (en)
HU (1) HUP9903734A3 (en)
IS (1) IS4706A (en)
MA (1) MA26410A1 (en)
MX (1) MX9804008A (en)
NO (1) NO982302L (en)
NZ (1) NZ322053A (en)
OA (1) OA10687A (en)
PE (1) PE22898A1 (en)
PL (1) PL326981A1 (en)
SK (1) SK63098A3 (en)
TN (1) TNSN96141A1 (en)
TR (1) TR199800902T2 (en)
WO (1) WO1997018814A1 (en)
YU (1) YU62096A (en)
ZA (1) ZA969722B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1282248A (en) * 1997-12-16 2001-01-31 辉瑞产品公司 Combination effective for treatment of impotence
AP1224A (en) 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
GT199900061A (en) * 1998-05-15 2000-10-14 Pfizer PHARMACEUTICAL FORMULATIONS.
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
CO5140079A1 (en) * 1998-10-14 2002-03-22 Novartis Ag PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
UA67802C2 (en) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US20030059467A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (en) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Oral matrix formulations of doxazosin
US20050255157A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (en) * 2004-05-28 2006-04-27 한미약품 주식회사 Sustained release composition for oral administration of niacin
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
KR100679111B1 (en) * 2004-11-20 2007-02-07 대우약품공업주식회사 A sustained release tablet comprising doxazosin
BRPI0614870A2 (en) * 2005-08-22 2011-04-19 Novartis Ag pharmaceutical compositions
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CN101489560B (en) 2006-04-26 2015-11-25 苏佩努斯制药公司 There is the oxcarbazepine controlled release preparation of S shape release profiles
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN100396282C (en) * 2006-07-25 2008-06-25 山东省医药工业研究所 Slow released doxazosin mesilate capsule and its prepn process
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009223061B2 (en) 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (en) * 2008-12-17 2010-12-24 동아제약주식회사 The controlled released pharmaceutical compsitions of udenafil for sustained release property
PL2395983T3 (en) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
CA2758976C (en) 2009-04-20 2015-02-03 Alain Baron Chemosensory receptor ligand-based therapies
JP2013512229A (en) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment of diabetic patients whose genotype has been identified with DDP-IV inhibitors such as linagliptin
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
BR112012028136A2 (en) 2010-05-05 2016-08-09 Boehringer Ingelheim Int combination therapy
MY161846A (en) 2010-07-09 2017-05-15 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
SG189444A1 (en) 2010-10-19 2013-05-31 Elcelyx Therapeutics Inc Chemosensory receptor ligand-based therapies
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
SI2661266T1 (en) 2011-01-07 2021-01-29 Anji Pharma (Us) Llc Chemosensory receptor ligand-based therapies
CN102058555A (en) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 Doxazosin controlled release tablet
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
CN102188431A (en) * 2011-05-09 2011-09-21 浙江九旭药业有限公司 Doxazosin mesylate sustained-release tablets and preparation method thereof
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN105431144A (en) 2013-06-05 2016-03-23 思康脑侒股份有限公司 Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN105616378A (en) * 2014-10-31 2016-06-01 康普药业股份有限公司 Fluconazole capsule and preparation method therefor
MX2018015089A (en) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinations of linagliptin and metformin.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198386B (en) * 1982-07-06 1988-12-21 Lepetit Spa A PROTRACTED RELEASE PRODUCT CONTAINING SULOCTIDYL
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992001445A1 (en) * 1990-07-23 1992-02-06 Alza Corporation Oral osmotic device for delivering nicotine

Also Published As

Publication number Publication date
YU62096A (en) 1999-03-04
SK63098A3 (en) 1999-05-07
CA2232715A1 (en) 1997-05-29
BG102438A (en) 1999-01-29
NO982302L (en) 1998-07-17
CN1215993A (en) 1999-05-05
OA10687A (en) 2002-11-27
TR199800902T2 (en) 1998-09-21
KR19990071505A (en) 1999-09-27
NO982302D0 (en) 1998-05-20
GB9523752D0 (en) 1996-01-24
HUP9903734A2 (en) 2000-03-28
JPH10513481A (en) 1998-12-22
TNSN96141A1 (en) 2005-03-15
IS4706A (en) 1998-03-31
CZ155498A3 (en) 1999-03-17
AP718A (en) 1999-01-06
WO1997018814A1 (en) 1997-05-29
AU7572196A (en) 1997-06-11
AR004335A1 (en) 1998-11-04
PE22898A1 (en) 1998-05-07
HRP960554A2 (en) 1998-02-28
MX9804008A (en) 1998-09-30
AU709560B2 (en) 1999-09-02
AP9600883A0 (en) 1997-01-31
EP0862437A1 (en) 1998-09-09
BR9611626A (en) 1999-06-01
MA26410A1 (en) 2004-12-20
NZ322053A (en) 1999-11-29
HUP9903734A3 (en) 2000-04-28
ZA969722B (en) 1998-05-20
PL326981A1 (en) 1998-11-09

Similar Documents

Publication Publication Date Title
CO4480020A1 (en) PHARMACEUTICAL FORMULATIONS
AR039744A1 (en) METHODS AND DOSAGE FORMS TO INCREASE THE SOLUBILITY OF PHARMACOS COMPOSITIONS FOR CONTROLLED ADMINISTRATION
AR030541A1 (en) AMYINOPROPYLPHOSPHINIC ACIDS, ITS USE FOR THE MANUFACTURE OF MEDICINES, AND PHARMACEUTICAL FORMULATION
AR065073A2 (en) A MEDICAMENT FORMULATION OF A MATRIX SYSTEM THAT HAS CONTROLLED RELEASE OF AN ACTIVE COMPOUND
CO5640072A2 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ATORVASTATIN MANUFACTURED WITHOUT GRANULATION
CY1107675T1 (en) TRAMADOLIS MEDICINES
AR040722A1 (en) FORMULATIONS AND DOSAGE FORMS FOR THE CONTROLLED ADMINISTRATION OF TOPIRAMATO
AR006678A1 (en) DERIVATIVES OF TRICYCLIC MACROLIDES, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, USE OF THEM TO PREPARE MEDICINES AND PROCEDURE FOR THEIR PREPARATION
PA8548701A1 (en) AZAINDOLS
CY1105648T1 (en) FILBANSERIN FOR THE TREATMENT OF EXTRAPYRAMIDAL MOVEMENT DISORDERS
SV1999000152A (en) CONTROLLED DRUG DELIVERY SYSTEM ORALLY ADMINISTERED, PROVIDING TEMPORARY AND SPACE CONTROL
BRPI0418026A (en) phenylalanine derivatives or pharmaceutically acceptable salts thereof, pharmaceutical composition, alpha4 integrin antagonist, and therapeutic or preventative agent for diseases
AR018862A1 (en) PHARMACEUTICAL FORMULATION OF PROLONGED RELEASE, IMPROVED FOR THE ORAL ADMINISTRATION OF NEFAZODONA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME; ORAL DOSAGE FORM THAT UNDERSTANDS AND USE OF SUCH FORMULATION TO PREPARE THE SUCH DOSAGE FORM
CO5160287A1 (en) FORMULATION OF CONTROLLED RELEASE OF DIVALPROEX SODICO
CY1106137T1 (en) PHARMACEUTICAL COMPOSITION PEPILAMVANOUS LUMIRACOXIB
ATE292453T1 (en) ANTIVIRAL DRUG
AR011919A1 (en) FORMULATION IN TABLETS OR SWALLOWING CAPSULES OF PARACETAMOL (N-ACETIL-P-AMINOFENOL) AND PROCEDURE TO PREPARE IT
NO962752L (en) Use of 2,3-diaryl-1-benzopyran derivatives in the manufacture of a medicament for the treatment and prevention of bone loss and osteoporosis
UY27539A1 (en) PHARMACEUTICAL FORMULATION
BR9809708A (en) Pharmaceutical compositions of peptides having low solubility in physiological medium
ES2194618T1 (en) ORALALLY DISINTEGRABLE COMPOSITION THAT MIRTAZAPINE INCLUDES.
JP2003055258A (en) Stabilized composition
AR035006A1 (en) DERIVATIVE OF NAFTIRIDIN-DIBENZO [A, D] CICLOHEPTENO-10-ACETICO, PHARMACEUTICAL COMPOSITION, AND THE USE OF THAT DERIVATIVE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
JP2003055223A (en) Stabilized composition
AR030551A1 (en) USE OF NEFIRACETAM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE PROCESSING OF THE RESULTING PHARMACEUTICAL NEURODEGENERATION AND COMPOSITION